Yutaka Seino Selected Research

Hypoglycemic Agents (Hypoglycemics)

11/2020	Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan.
6/2019	GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.
7/2018	Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.
7/2018	Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.
1/2018	Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
1/2018	Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open-label, multicenter study.
9/2017	Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.
1/2017	Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
1/2016	Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.
7/2015	Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yutaka Seino Research Topics

Disease

110	Type 2 Diabetes Mellitus (MODY) 08/2022 - 05/2002
28	Insulin Resistance 02/2019 - 07/2002
26	Body Weight (Weight, Body) 12/2021 - 04/2003
22	Diabetes Mellitus 05/2019 - 01/2002
21	Hypoglycemia (Reactive Hypoglycemia) 07/2018 - 09/2006
16	Hyperglycemia 10/2017 - 01/2002
15	Obesity 12/2022 - 07/2002
15	Glucose Intolerance 01/2021 - 03/2003
8	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 09/2018 - 08/2002
6	Weight Gain 09/2021 - 04/2014
4	AIDS-Related Complex (ARC) 12/2022 - 06/2019
4	Cardiovascular Diseases (Cardiovascular Disease) 05/2022 - 12/2013
4	Myocardial Infarction 01/2021 - 05/2017
4	Constipation 01/2021 - 10/2011
4	Weight Loss (Weight Reduction) 08/2020 - 10/2010
4	Diabetes Complications 12/2013 - 09/2008
3	Anorexia 10/2021 - 06/2019
3	Albuminuria 01/2020 - 03/2014
3	Heart Failure 01/2020 - 05/2017
3	Hypertension (High Blood Pressure) 10/2016 - 04/2008
3	Ketosis 06/2015 - 08/2008
3	Diabetic Nephropathies (Diabetic Nephropathy) 03/2014 - 08/2005
3	Bone Fractures (Bone Fracture) 12/2013 - 07/2006
2	Neoplasms (Cancer) 10/2021 - 06/2019
2	Stroke (Strokes) 01/2021 - 01/2020
2	Infections 12/2020 - 10/2010
2	Pain (Aches) 12/2020 - 12/2018
2	Sarcopenia 06/2019 - 06/2015
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 03/2019 - 01/2017
2	Nausea 01/2018 - 11/2015
2	Non-alcoholic Fatty Liver Disease 01/2015 - 03/2013
2	Bone Resorption 02/2014 - 02/2008
2	Cognitive Dysfunction 12/2013 - 03/2013
2	Coronary Artery Disease (Coronary Atherosclerosis) 03/2013 - 10/2009

Drug/Important Bio-Agent (IBA)

59	Glucose (Dextrose)FDA LinkGeneric 12/2022 - 11/2002
35	Insulin (Novolin)FDA Link 12/2021 - 01/2002
20	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2022 - 02/2008
19	Hypoglycemic Agents (Hypoglycemics)IBA 11/2020 - 12/2004
18	Liraglutide FDA Link 08/2022 - 01/2011
17	IncretinsIBA 05/2017 - 01/2007
16	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 01/2020 - 07/2014
14	Glucagon-Like Peptide-1 ReceptorIBA 01/2021 - 02/2008
13	Pharmaceutical PreparationsIBA 10/2021 - 12/2006
12	Blood Glucose (Blood Sugar)IBA 12/2021 - 07/2004
12	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 09/2021 - 04/2003
10	Glucagon (Glukagon)FDA Link 12/2021 - 11/2008
10	Sitagliptin Phosphate (Januvia)FDA Link 01/2021 - 01/2011
9	Triglycerides (Triacylglycerol)IBA 01/2018 - 10/2003
9	alogliptinIBA 05/2017 - 09/2011
8	Dipeptidyl-Peptidase IV InhibitorsIBA 05/2022 - 06/2009
8	Sodium-Glucose Transporter 2 InhibitorsIBA 05/2022 - 12/2014
8	gastric inhibitory polypeptide receptorIBA 01/2021 - 07/2002
7	SodiumIBA 05/2022 - 04/2016
7	Glucagon-Like Peptide-1 Receptor AgonistsIBA 12/2021 - 05/2011
7	lixisenatideIBA 12/2021 - 01/2015
7	AdiponectinIBA 02/2013 - 10/2005
6	Peptides (Polypeptides)IBA 10/2021 - 05/2011
6	LeptinIBA 02/2013 - 02/2004
5	glimepiride (Amarel)FDA LinkGeneric 01/2021 - 10/2011
5	Sodium-Glucose Transport ProteinsIBA 01/2020 - 07/2014
5	Hormones (Hormone)IBA 01/2017 - 02/2004
5	C-PeptideIBA 11/2015 - 08/2008
5	LipidsIBA 01/2015 - 03/2005
4	empagliflozinIBA 05/2022 - 03/2019
4	semaglutideIBA 01/2022 - 01/2018
4	AutoantibodiesIBA 10/2021 - 07/2003
4	LinagliptinIBA 01/2021 - 10/2016
4	rGLP-1 proteinIBA 09/2017 - 12/2009
4	C-Reactive ProteinIBA 02/2013 - 12/2002
3	GhrelinIBA 10/2021 - 06/2019
3	ninjin'yoeitoIBA 10/2021 - 06/2019
3	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 06/2019
3	Proteins (Proteins, Gene)FDA Link 08/2020 - 03/2008
3	AlbuminsIBA 01/2020 - 02/2013
3	Metformin (Glucophage)FDA LinkGeneric 07/2018 - 12/2012
3	Glyburide (Glibenclamide)FDA LinkGeneric 04/2016 - 07/2014
3	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 02/2013 - 10/2005
3	Streptozocin (Streptozotocin)FDA Link 09/2011 - 02/2002
3	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 06/2009 - 07/2002
3	corosolic acidIBA 04/2008 - 07/2004
3	Adenosine Triphosphate (ATP)IBA 08/2006 - 12/2004
2	Fura-2 (Fura 2)IBA 12/2022 - 06/2019
2	ipragliflozinIBA 01/2021 - 01/2021
2	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2020
2	Dietary Fiber FDA Link 08/2020 - 06/2013
2	Fatty Acids (Saturated Fatty Acids)IBA 08/2020 - 08/2014
2	CarbohydratesIBA 08/2020 - 01/2017
2	Appetite Depressants (Anorectics)IBA 01/2020 - 06/2019
2	2,4-thiazolidinedione (thiazolidinedione)IBA 07/2018 - 01/2018
2	saxagliptin FDA Link 12/2017 - 05/2017
2	EnzymesIBA 01/2015 - 09/2014
2	Insulin Glargine (Lantus)FDA Link 12/2014 - 12/2013
2	Hemoglobins (Hemoglobin)IBA 07/2014 - 05/2007
2	Biological ProductsIBA 12/2013 - 03/2013
2	CalciumIBA 10/2013 - 07/2006

Therapy/Procedure

29	Glycemic Control 09/2021 - 10/2005
27	Therapeutics 01/2021 - 03/2003
3	Kampo Medicine (Kampo) 10/2021 - 06/2019
3	Transplantation 10/2011 - 02/2002
3	Islets of Langerhans Transplantation 03/2008 - 09/2006